Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

I-Mab (IMAB)

39   0.78 (2.04%) 09-29 01:33
Open: 38.3 Pre. Close: 38.22
High: 39.5099 Low: 37.8901
Volume: 90,275 Market Cap: 2,749M
I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 185 full-time employees.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 39.53 - 39.725 39.725 - 39.922
Low: 37.44 - 37.639 37.639 - 37.84
Close: 38.676 - 38.995 38.995 - 39.319

Technical analysis

as of: 2020-09-28 4:33:59 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 49.41     One year: 57.71
Support: Support1: 34.45    Support2: 29.60
Resistance: Resistance1: 42.30    Resistance2: 49.41
Pivot: 38.51
Moving Average: MA(5): 39.56     MA(20): 38.02
MA(100): 29.62     MA(250):
MACD: MACD(12,26): 1.78     Signal(9): 1.90
Stochastic oscillator: %K(14,3): 51.16     %D(3): 64.52
RSI: RSI(14): 57.17
52-week: High: 42.30  Low: 9.30  Change(%): 212.0
Average Vol(K): 3-Month: 15324  10-Days: 17531

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
IMAB has closed below upper band by 40.3%. Bollinger Bands are 30.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sun, 20 Sep 2020
Analysts Are Betting On I-Mab (NASDAQ:IMAB) With A Big Upgrade This Week - Yahoo Finance

Tue, 15 Sep 2020
I-Mab inks multi-billion dollar deal with AbbVie - The Pharma Letter

Wed, 09 Sep 2020
I-Mab (IMAB) Surges: Stock Moves 5.5% Higher - Yahoo Finance

Tue, 08 Sep 2020
I-Mab Announces Upcoming Participation at September Conferences English English - PRNewswire

Tue, 08 Sep 2020
AbbVie I-Mab Cancer Deal, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha

Fri, 04 Sep 2020
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium - PRNewswire

Financial Analysis

Growth n/a
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability n/a
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 71
Shares Float (M) 24
% Held by Insiders 0.99
% Held by Institutions 0.92
Shares Short (K) 15
Shares Short P. Month (K) 19

Stock Financials

EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm) -39.2
Return on Equity (ttm) -74.3
Qtrly Rev. Growth
Gross Profit (p.s.) 0.426
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.